TG Therapeutics' (TGTX) "Buy" Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of TG Therapeutics (NASDAQ:TGTX - Free Report) in a report published on Wednesday,Benzinga reports. They currently have a $55.00 price objective on the biopharmaceutical company's stock.

A number of other equities research analysts have also commented on TGTX. JPMorgan Chase & Co. increased their price objective on shares of TG Therapeutics from $30.00 to $43.00 and gave the stock an "overweight" rating in a report on Monday, November 25th. The Goldman Sachs Group upped their price objective on TG Therapeutics from $20.00 to $22.00 and gave the stock a "neutral" rating in a report on Tuesday, November 5th. StockNews.com upgraded TG Therapeutics from a "sell" rating to a "hold" rating in a research report on Tuesday, January 7th. Finally, TD Cowen started coverage on TG Therapeutics in a research report on Tuesday, October 29th. They set a "buy" rating and a $50.00 target price for the company. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $40.67.

TG Therapeutics Price Performance

TG Therapeutics stock traded up $0.44 during mid-day trading on Wednesday, hitting $30.18. 2,982,848 shares of the company were exchanged, compared to its average volume of 3,285,693. TG Therapeutics has a 1-year low of $12.84 and a 1-year high of $36.84. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27. The business has a fifty day moving average of $31.63 and a 200 day moving average of $25.60. The company has a market capitalization of $4.70 billion, a PE ratio of -301.77 and a beta of 2.24.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last issued its quarterly earnings data on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.01). The firm had revenue of $83.90 million for the quarter, compared to the consensus estimate of $81.68 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. TG Therapeutics's quarterly revenue was down 49.4% compared to the same quarter last year. During the same period in the prior year, the company posted $0.73 earnings per share. As a group, sell-side analysts expect that TG Therapeutics will post 0.17 earnings per share for the current year.

Insider Transactions at TG Therapeutics

In related news, Director Sagar Lonial sold 5,000 shares of the company's stock in a transaction on Monday, November 11th. The shares were sold at an average price of $30.44, for a total value of $152,200.00. Following the completion of the sale, the director now owns 100,195 shares in the company, valued at $3,049,935.80. This represents a 4.75 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Sean A. Power sold 10,021 shares of TG Therapeutics stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $28.53, for a total value of $285,899.13. Following the transaction, the chief financial officer now owns 660,611 shares in the company, valued at approximately $18,847,231.83. This represents a 1.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 26,358 shares of company stock worth $781,497 in the last three months. Insiders own 10.50% of the company's stock.

Institutional Investors Weigh In On TG Therapeutics

A number of hedge funds have recently modified their holdings of TGTX. Victory Capital Management Inc. raised its holdings in TG Therapeutics by 24.6% during the 2nd quarter. Victory Capital Management Inc. now owns 26,212 shares of the biopharmaceutical company's stock worth $466,000 after buying an additional 5,169 shares during the period. State of New Jersey Common Pension Fund D bought a new stake in TG Therapeutics in the 2nd quarter valued at $2,022,000. XTX Topco Ltd acquired a new position in TG Therapeutics in the 2nd quarter worth $395,000. Hood River Capital Management LLC increased its holdings in TG Therapeutics by 6.7% during the 2nd quarter. Hood River Capital Management LLC now owns 1,572,929 shares of the biopharmaceutical company's stock worth $27,982,000 after purchasing an additional 98,892 shares in the last quarter. Finally, Marshall Wace LLP acquired a new stake in shares of TG Therapeutics in the 2nd quarter valued at about $36,501,000. Institutional investors and hedge funds own 58.58% of the company's stock.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.